

IPAR



Publicly Available Assessment Report for a **Veterinary Medicinal Product**

Zantel

PRODUCT SUMMARY

EU Procedure number	IE/V/0152/001
Name, strength and pharmaceutical form	Zantel
Active substances	Praziquantel, Fenbendazole
Applicant	Chanelle Pharmaceuticals Manufacturing Ltd. Loughrea Co. Galway Ireland
Legal basis of application	Fixed combination application in accordance with Article 13b of Directive 2001/82/EC as amended.
Date of Authorisation	04/11/2003
Target species	Dogs
Indication for use	A broad spectrum anthelmintic for the treatment of mixed infections by nematodes and cestodes in dogs.
ATCvet code	QP52AA51
Concerned Member States	BE, DK, EL, ES, FI, FR, IT, LI, LU, NL, NO, UK, CZ, SK

PUBLIC ASSESSMENT REPORT

The public assessment report reflects the scientific conclusion reached by the HPRA at the end of the evaluation process and provides a summary of the grounds for approval of the marketing authorisation for the specific veterinary medicinal product. It is made available by the HPRA for information to the public, after the deletion of commercially confidential information. The legal basis for its creation and availability is contained in Article 25.4 of EC Directive 2001/82/EC as amended by Directive 2004/28/EC for veterinary medicinal products. It is a concise document which highlights the main parts of the documentation submitted by the applicant and the scientific evaluation carried out by the HPRA leading to the approval of the product for marketing in Ireland.

The Summary of Product Characteristics (SPC) for this product is available on the HPRA's website.

I SCIENTIFIC OVERVIEW

The initial application for the product was assessed before there was a requirement to have a public assessment report, therefore no details in this section are available. Please refer to Section VI for significant post-approval changes which are important for the quality, safety and efficacy of the product.

II QUALITY ASPECTS

See section I.

III SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)

See section 1.

IV CLINICAL ASSESSMENT (EFFICACY)

See section 1.

V OVERALL CONCLUSION AND BENEFIT/RISK ASSESSMENT

On the basis of the original data submitted, the HPRA considered that the product demonstrated adequate evidence of efficacy for the approved indications as well as a satisfactory benefit/risk profile and therefore granted a marketing authorisation.

VI POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the HPRA website.

Changes:

None.